These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38772804)

  • 1. Estimating Taiwan's QALY league table for catastrophic illnesses: Providing real-world evidence to integrate prevention with treatment for resources allocation.
    Wang JD; Lai WW; Yang SC; Huang WY; Hwang JS
    J Formos Med Assoc; 2024 May; ():. PubMed ID: 38772804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QALYs and medical costs saved from prevention of a cancer: Analysis of nation-wide real-world data of Taiwan with lifetime horizon.
    Lai WW; Chung CH; Lin CN; Yang SC; Hwang JS; Wang JD
    J Formos Med Assoc; 2021 Dec; 120(12):2089-2099. PubMed ID: 34020855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of work-related cancers in Taiwan-Estimation with QALY (quality-adjusted life year) and healthcare costs.
    Lee LJ; Lin CK; Hung MC; Wang JD
    Prev Med Rep; 2016 Dec; 4():87-93. PubMed ID: 27413666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lifetime burden following stroke: Long term impact of stroke on survival and quality of life.
    Cheon S; Li CY; Jeng JS; Wang JD; Ku LE
    Int J Stroke; 2023 Aug; 18(7):795-803. PubMed ID: 36912208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the lifelong health impact and financial burdens of different types of lung cancer.
    Yang SC; Lai WW; Su WC; Wu SY; Chen HH; Wu YL; Hung MC; Wang JD
    BMC Cancer; 2013 Dec; 13():579. PubMed ID: 24308346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan.
    Hung MC; Lu HM; Chen L; Lin MS; Chen CR; Yu CJ; Wang JD
    PLoS One; 2012; 7(9):e44043. PubMed ID: 22970160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of expected health impacts for major cancers: integration of incidence rate and loss of quality-adjusted life expectancy.
    Hung MC; Lai WW; Chen HH; Su WC; Wang JD
    Cancer Epidemiol; 2015 Feb; 39(1):126-32. PubMed ID: 25553846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of cancer treatment in Taiwan.
    Hung MC; Lai WW; Chen HH; Lee JC; Lin YJ; Hsiao JR; Cheng YM; Shan YS; Su WC; Wang JD
    J Formos Med Assoc; 2016 Aug; 115(8):609-18. PubMed ID: 27302557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data.
    Chang KC; Lee KY; Lu TH; Hwang JS; Lin CN; Ting SY; Chang CC; Wang JD
    Drug Alcohol Depend; 2019 Aug; 201():197-204. PubMed ID: 31247504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Quality-Adjusted Life Expectancy of Patients With Oral Cancer: Integration of Lifetime Survival With Repeated Quality-of-Life Measurements.
    Chung CH; Hu TH; Wang JD; Hwang JS
    Value Health Reg Issues; 2020 May; 21():59-65. PubMed ID: 31655464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of percutaneous coronary intervention versus medical therapy in patients with acute myocardial infarction: real-world and lifetime-horizon data from Taiwan.
    Liao CT; Hsieh TH; Shih CY; Liu PY; Wang JD
    Sci Rep; 2021 Mar; 11(1):5608. PubMed ID: 33692425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: adjusting quality-of-life and lead-time bias for utility of surgery.
    Yang SC; Lai WW; Chang HY; Su WC; Chen HH; Wang JD
    Lung Cancer; 2014 Oct; 86(1):96-101. PubMed ID: 25178685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
    Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
    J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
    Iannazzo S; Carsi M; Chiroli S
    Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
    Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
    Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of life expectancy and healthcare cost in rheumatoid arthritis patients with and without depression: a population-based retrospective cohort study.
    Chiu YM; Lan JL; Huang WL; Wu CS
    Front Med (Lausanne); 2023; 10():1221393. PubMed ID: 38020149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
    Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.